# US 2008/0306028 A1 · Erianin Salts, Their Preparation Methods and Pharmaceutical Compositions Containing the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306028 A1
- Document ID: US20080306028A1
- Status: Published application
- Kind: A1
- Application number: 11/997,595
- Filed: 2006-08-01
- Published: 2008-12-11
- Earliest claimed: 2005-08-02
- Assignees: The Jiang Cell Biomedical Research Co., Ltd.
- Inventors: Yiping Li; Ning Li
- Web page: https://patentgrep.com/patent/US20080306028A1

## CPC

- C07C 305/04: being acyclic and saturated
- A61P 35/00: Antineoplastic agents
- C07F 9/12: with hydroxyaryl compounds
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

This invention relates to a kind of Erianin salt and the preparing process thereof. The said Erianin salt is a compound with the following general formula (I), wherein R is the salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, organic amine. This invention also relates to a pharmaceutical composition comprising Erianin salt. Compared with Erianin, the said Erianin salt has far better solubility, which can improve the bioavailability and show better antineoplastic efficacy.

## Claims

### Claim 1

A pharmaceutically acceptable salt of Erianin represented by the following general formula (I):
wherein:
R is a salt formed by monobasic acid radical of inorganic oxacid combining with metals, ammonium salts, or organic amine;
said metals are selected from a group consisting of alkali metals and alkali-earth metals;
said inorganic oxacid is selected from a group consisting of phosphoric acid, sulphuric acid, sulfurous acid, nitric acid, carbonic acid, hypochoric acid and trifluoroacetic acid.

### Claim 2 (depends on 1)

The pharmaceutically acceptable salt of Erianin as claim 1, wherein said pharmaceutically acceptable salt of Erianin is an organic phosphate of Erianin or a sulphate of Erianin.

### Claim 3 (depends on 2)

The pharmaceutically acceptable salt of Erianin as claim 2, wherein said pharmaceutically acceptable salt of Erianin is organic phosphate of Erianin represented by the following general formula (II):

### Claim 4 (depends on 3)

The pharmaceutically acceptable salt of Erianin as claim 3, wherein in formula (II), R1 is Na, R2 is Na, and the said Erianin salt is disodium organic phosphate of Erianin.

### Claim 5 (depends on 2)

The pharmaceutically acceptable salt of Erianin as claim 2, wherein said pharmaceutically acceptable salt of Erianin is sulphate salt of Erianin represented by the following general formula (III):
Wherein: R3 is Na, K, or NH4.

### Claim 6 (depends on 5)

The pharmaceutically acceptable salt of Erianin as claim 5, wherein in formula (III), R3 is Na, and the said Erianin salt is sodium sulphate of Erianin.

### Claim 7

A process for preparing a pharmaceutically acceptable salt of Erianin comprising the following steps:
A1. reacting Erianin with phosphorylating agent by phosphorylating reaction of the phenolic hydroxyl in the presence of acid binding agent to form compound (IV), an intermediate of the phosphorylated Erianin, the reacting temperature being 25˜80° C. and the reacting solvent being an inert organic solvent;
A2. reacting the reaction liquid obtained in step A1 with alkali directly to obtain compound (II), an organic phosphate salt of Erianin;
The synthetic route is:
in formula (IV), R4, R5 is independently Obut, Cl or Br respectively, but represents tert-butyl group; in formula (II), R1, R2 is independently H, Na, K, or NH4 respectively, and R1 and R2 are not H simultaneously.

### Claim 8 (depends on 7)

The process as claim 7, wherein in step A1:
said phosphorylating agent is selected from a group consisting of OPCl3, OPBr3, and (ButO)2P(O)Cl;
said acid binding agent is selected from a group consisting of pyridinium, monalkylamine, dialkylamine and tri alkylamine;
said inert organic solvent is selected from a group consisting of dichlormethane, dichlorethane, benzene, carbon tetrachloride and acetonitrile.
in step A2:
said alkali is selected from a group consisting of NaOH, KOH, NaOCH3, KOCH3, NaOCH2CH3, and KOCH2CH3.

### Claim 9 (depends on 7)

The process as claim 7, wherein in step A1, the phosphorylating agent is OPCl3, and the acid binding agent is triethylamine; in step A2, the alkali is NaOH.

### Claim 10

A process for preparing a pharmaceutically acceptable salt of Erianin, comprising the following steps:
B1. under the protection of inert gas, reacting Erianin with dibenzylphosphorite in the presence of acid binding agent by phosphorylating reaction of the phenolic hydroxyl to obtain compound (V), the reaction temperate being −40° C.˜−10° C., the reaction is carried out in inert organic solvent;
B2. under the protection of inert gas, reacting compound (V) with NaI in the presence of active group protection agent to obtain compound (VI), the reaction is carried out in inert organic solvent;
B3. reacting compound (VI) with alkali to obtain compound (II),
the synthetic route is:
in formula (V), bn represents benzyl group; in formula (II), R1, R2 is independently H, Na, K, or NH4 respectively, and R1 and R2 are not H simultaneously.

### Claim 11 (depends on 10)

The process as claim 10, wherein in step B1:
said acid binding agent is selected from a group consisting of pyridinium, monalkylamine, dialkylamine, tri alkylamine and dimethylamino pyridine;
said inert organic solvent is selected from a group consisting of dichlormethane, dichlorethane, benzene, carbon tetrachloride and acetonitrile;
in step B2:
said inert organic solvent is selected from a group consisting of dichlormethane, dichlorethane, benzene, carbon tetrachloride and acetonitrile;
in step B3:
said alkali is selected from a group consisting of NaOH, KOH, NaOCH3, KOCH3, NaOCH2CH3 and KOCH2CH3.

### Claim 12 (depends on 10)

The process as claim 10, wherein in step B1,
said acid binding agent is diisopropylethylamine and dimethylamino pyridine, and the inert gas is argon;
in step B2, the inert gas is argon, the protecting agent of active group is trimethyl chloride silane, and the inert organic solvent is acetonitrile and/or carbon tetrachloride;
in step B3, the alkali is sodium hydroxide.

### Claim 13

A process for preparing a pharmaceutically acceptable salt of Erianin, comprising the following steps:
C1. reacting Erianin with halo sulfonic acid by sulfonylating reaction of phenolic hydroxyl in the presence of acid binding agent to obtain compound (VII), an intermediate of the sulfonylated Erianin, the reacting temperate being −5˜−10° C. and the reacting solvent being an inert organic solvent;
C2. reacting the reacting liquid obtained in step C1 with alkali directly to prepare compound (III), a sodium sulfate of Erianin;
the synthetic route is:
in formula (VII), R6 is Cl or Br; in formula (III), R3 is Na, K, or NH4.

### Claim 14 (depends on 13)

The process as claim 13, wherein in step C1:
said halogen sulfonic acid is chlorosulfonic acid or bromo sulfonic acid;
said acid binding agent is selected from a group consisting of pyridinium, monalkylamine, dialkylamine and trialkylamine;
said inert organic solvent is selected from a group consisting of dichlormethane, dichlorethane, benzene, and carbon tetrachloride;
in step C2:
said alkali is selected from a group consisting of NaOH, KOH, NaOCH3, KOCH3, NaOCH2CH3 and KOCH2CH3.

### Claim 15 (depends on 13)

The process as claim 13, wherein in step C1,
the halo sulfonic acid is chlorosulfonic acid, the acid binding agent is N,N-dimethylaniline, and the inert organic solvent is dichloromethane;
in step C2, the alkali is NaOH.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 1 amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.

### Claim 17 (depends on 16)

The pharmaceutical composition as claim 16, wherein said pharmaceutical composition is in the form of preparation for injection or oral administration.

### Claim 18 (depends on 1)

A use of the pharmaceutically acceptable salt of Erianin of claim 1 in preparing an antitumor pharmaceutical.

### Claim 19 (depends on 2)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 2 in amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.

### Claim 20 (depends on 3)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 3 in amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.

### Claim 21 (depends on 4)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 4 in amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.

### Claim 22 (depends on 5)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 5 in amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.

### Claim 23 (depends on 6)

A pharmaceutical composition comprising an efficient amount of pharmaceutically acceptable salt of Erianin as claim 6 in amount effective to treat diseases together with a pharmaceutically acceptable carrier and/or excipient.
